NCT05187832View on ClinicalTrials.gov

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Advanced or Metastatic Breast Cancer
Interventions
DRUG

AND019 PO QD

AND019 administrated as oral capsule once per day for 28 days for each cycle

Trial Locations (1)

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

Sponsors
All Listed Sponsors
lead

Kind Pharmaceuticals LLC

INDUSTRY